Genetic platform for OA

About Rottapharm Biotech

Rottapharm Biotech is a private, clinical-stage biotech firm with a heritage of over 50 years in drug discovery, now operating as an independent innovator. Its pipeline features advanced candidates in oncology and osteoarthritis, including vorbipiprant (in Phase I/II for GI cancers) and CR10049 (a first-in-class intra-articular kinase inhibitor for inflammatory OA). The company's strategy balances proprietary development with external collaborations to de-risk and accelerate its programs toward key clinical milestones.

Therapeutic Areas